Invivyd IVVD
NASDAQ IVVD
$0.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Invivyd (IVVD) Net Cash Flow (2021 - 2025)

Invivyd's (IVVD) quarterly Net Cash Flow came in at $141.7 million in Q4 2025, up 477.64% on a YoY basis from $24.5 million in Q4 2024, and up 183.09% quarter-over-quarter from $50.1 million in Q3 2025.

Analysis

Invivyd (IVVD) Net Cash Flow (2021 - 2025) Analysis & Trends

Invivyd (IVVD) has reported Net Cash Flow for 5 consecutive years, with $141.7 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 477.64% year-over-year to $141.7 million; the trailing twelve-month figure through Dec 2025 stood at $157.3 million (up 219.83% YoY), and the FY2025 full-year result was $157.3 million, up 219.83% from the prior year.
  • Net Cash Flow advanced to $141.7 million in Q4 2025 per IVVD's latest filing, from $50.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $301.3 million in Q2 2021 and bottomed at -$196.7 million in Q3 2022.
  • Historically, Net Cash Flow has averaged $5.6 million across 5 years, with a median of -$10.6 million in 2022.
  • The sharpest annual moves came in 2024 and 2025: Net Cash Flow tumbled 817.08% in 2024, then soared 477.64% in 2025.
  • Over 5 years, Net Cash Flow stood at $64.0 million in 2021, then sank by 390.95% to -$186.1 million in 2022, then surged by 110.11% to $18.8 million in 2023, then tumbled by 299.42% to -$37.5 million in 2024, then jumped by 477.64% to $141.7 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods registered $141.7 million, $50.1 million, and -$13.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Cash Flow (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 1.95 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn -4.43 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 652.90 Mn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn -504.30 Mn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn -
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn -183.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn -496,000.00
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn -2.09 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn -37.14 Mn
10 Invivyd 244.65 Mn 84.57 Mn 13.01 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 141.72 Mn
Sep 30, 2025 50.06 Mn
Jun 30, 2025 -13.18 Mn
Mar 31, 2025 -21.26 Mn
Dec 31, 2024 -37.53 Mn
Sep 30, 2024 -41.01 Mn
Jun 30, 2024 -41.51 Mn
Mar 31, 2024 -11.25 Mn
Dec 31, 2023 18.82 Mn
Sep 30, 2023 59.88 Mn
Jun 30, 2023 -4.53 Mn
Mar 31, 2023 34.40 Mn
Dec 31, 2022 -186.08 Mn
Sep 30, 2022 -196.73 Mn
Jun 30, 2022 -57.34 Mn
Mar 31, 2022 -10.00 Mn
Dec 31, 2021 63.96 Mn
Sep 30, 2021 85.76 Mn
Jun 30, 2021 301.26 Mn
Mar 31, 2021 -23.74 Mn